Inovio Pharmaceuticals, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 10, 2026, disclosing going-concern uncertainty and details on the commercial launch of its FDA-approved product VOCERYQ.

Key Highlights

  • Going-concern warning: According to the filing, the company "does not currently have sufficient working capital to fund our planned operations beyond the fourth quarter 2027 and substantial doubt exists as to our ability to continue as a going concern."
  • Cash and equivalents: The company reported cash and cash equivalents of $46,962,549 as of September 30, 2026, compared with $44,273,319 as of December 31, 2025.
  • Short-term investments declined: Short-term investments fell to $1,398,734 as of September 30, 2026, from $14,239,145 as of December 31, 2025.
  • Total assets decreased: Total assets were $60,136,243 as of September 30, 2026, down from $74,310,035 as of December 31, 2025.
  • VOCERYQ FDA accelerated approval: The filing states that VOCERYQ has received FDA accelerated approval, though continued approval may be contingent on confirmatory studies.
  • Shares outstanding: As of November 10, 2026, the company reported 187,306,884 shares of common stock outstanding.
  • Competing product risk: The filing identifies PAPZIMEOS as "an approved competing treatment for RRP" that poses competition to VOCERYQ.

Inovio's Financial Position and VOCERYQ Commercialization as of September 30, 2026

Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a smaller reporting company and non-accelerated filer incorporated in Delaware, filed its quarterly report covering the three months ended September 30, 2026. The filing identifies a significant liquidity concern, stating that the company does not have sufficient working capital to fund planned operations beyond the fourth quarter of 2027, and that "substantial doubt exists as to our ability to continue as a going concern." The company disclosed that it will need "substantial additional capital" for the commercialization of VOCERYQ and to develop its DNA medicines and proprietary device technology.

On the balance sheet, total current assets stood at $51,441,661 as of September 30, 2026, compared with $61,123,346 at December 31, 2025. The decline was driven primarily by a reduction in short-term investments, which decreased from $14,239,145 to $1,398,734 over the same period. Total liabilities included accounts payable and accrued expenses of $13,375,264 and accrued clinical trial expenses of $1,326,394 as of September 30, 2026. Investments in an affiliated entity, which stood at $2,103,688 at year-end 2025, fell to zero by September 30, 2026, according to the filing.

Regarding commercialization, the filing disclosed that VOCERYQ, which targets recurrent respiratory papillomatosis (RRP), received FDA accelerated approval, but noted that "continued approval for this indication may be contingent upon verification and description of clinical benefit in one or more confirmatory studies." The company disclosed that it relies on Syneos Health as its contract sales organization and has engaged third-party logistics, specialty distributor, specialty pharmacy, and patient HUB partners to support VOCERYQ's commercialization. The filing also warned that the company "has incurred significant losses in recent years, expects to incur significant net losses in the foreseeable future and may never become profitable."

What Was Disclosed

Inovio's 10-Q for Q3 2026 disclosed going-concern uncertainty, a decline in total assets from $74,310,035 to $60,136,243, details on the FDA-accelerated approval of VOCERYQ, and reliance on third-party partners for commercialization activities.